PACELLI PAOLA

Paola
Pacelli
Ricercatore Legge 240/10 - tempo determinato

Teaching activities

Completion accademic year: 2024/2025

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2022/2023
Course year: 3 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2022/2023

Completion accademic year: 2023/2024

Course year: 3 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2021/2022
Course year: 3 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2021/2022

Completion accademic year: 2022/2023

Research

Ultime pubblicazioni:

  • Pacelli, P., Sicuranza, A., Bestoso, E., Iurlo, A., Abruzzese, E., Santoni, A., et al. (2023). Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase. HEMATO, 1-8 [10.20944/preprints202304.0616.v1]. - view more
  • Pacelli, P., Santoni, A., Sicuranza, A., Abruzzese, E., Giai, V., Crugnola, M., et al. (2023). Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells. FRONTIERS IN PHARMACOLOGY, 14, 1-11 [10.3389/fphar.2023.1194712]. - view more
  • Abruzzese, E., Bocchia, M., Trawinska, M.M., Raspadori, D., Bondanini, F., Sicuranza, A., et al. (2023). Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). CANCERS, 15(16), 1-10 [10.3390/cancers15164112]. - view more
  • Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., et al. (2023). Anti-BCMA novel therapies for multiple myeloma. CANCER DRUG RESISTANCE, 6(1), 169-181 [10.20517/cdr.2022.138]. - view more
  • Cencini, E., Sicuranza, A., Fabbri, A., Marzano, C., Pacelli, P., Caroni, F., et al. (2023). The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study. LEUKEMIA & LYMPHOMA, 1-9 [10.1080/10428194.2023.2232490]. - view more